Anika Therapeutics, Inc.
ANIK
$14.88
-$0.14-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.67% | -5.91% | 30.55% | 16.51% | 4.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.67% | -5.91% | 30.55% | 16.51% | 4.61% |
| Cost of Revenue | 7.59% | 13.18% | 124.11% | 71.92% | 34.66% |
| Gross Profit | -5.79% | -16.71% | -2.41% | -5.70% | -8.08% |
| SG&A Expenses | 1.06% | -11.64% | 68.73% | 25.23% | 11.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.21% | -0.43% | 86.40% | 43.92% | 22.11% |
| Operating Income | -95.33% | -145.85% | -160.31% | -167.99% | -157.60% |
| Income Before Tax | -117.35% | -236.72% | -144.63% | -149.44% | -135.60% |
| Income Tax Expenses | -86.61% | -88.92% | -66.37% | -45.11% | -26.40% |
| Earnings from Continuing Operations | -2.28% | -13.04% | -244.31% | -350.94% | -318.57% |
| Earnings from Discontinued Operations | 100.03% | 98.11% | 33.38% | -45,319.05% | -1,694.92% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.50% | 80.70% | 66.12% | 18.27% | 26.14% |
| EBIT | -95.33% | -145.85% | -160.31% | -167.99% | -157.60% |
| EBITDA | -549.01% | -558.59% | -132.66% | -127.68% | -107.09% |
| EPS Basic | 79.57% | 80.25% | 65.67% | 18.14% | 26.12% |
| Normalized Basic EPS | -156.54% | -345.16% | -144.32% | -146.56% | -131.63% |
| EPS Diluted | 79.28% | 79.86% | 65.52% | 17.95% | 26.12% |
| Normalized Diluted EPS | -155.98% | -344.07% | -144.12% | -146.28% | -131.63% |
| Average Basic Shares Outstanding | -3.24% | -2.60% | -2.21% | -1.40% | -0.33% |
| Average Diluted Shares Outstanding | -2.41% | -1.77% | -1.90% | -1.09% | -0.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |